24 October 2016, at Brain Blooming, Oktay Ismail Kaplan from Medeniyet University is going to be at REMER.
What about topic of seminar?
Uncovering Molecular Barriers to Direct Cell Reprogramming Successful cell replacement therapies for Alzheimer’s, Diabetes and Parkinson diseases aim to replace lost cell types by introducing the necessary cell types into the damaged tissues. One way to generate desired cell types involves reprogramming of available cell types into a stem cell-like state called iPS (induced Pluripotent Stem) cells using a cocktail of transcription factors. iPS cells can be, in principle, subsequently re-differentiated into any cell types as proven through generation of mice from iPS cells though therapeutic use of iPS cells might bear risks such as introduction of mutations or teratoma formation. Alternatively, direct cell fate conversion can produce the desired cell types by skipping the initial step of generating proliferative pluripotent cells. However, many cells display resistance to be reprogrammed directly into other cell types probably due to the absence of “co-activators” or presence of “inhibitory factors” required for cell reprogramming. My primary research goals are directed towards uncovering novel regulators of cell fate reprogramming in vivo and thereby facilitate tissue replacement in living organisms. I will present my postdoctoral work, which has revealed that epithelial cells can be reprogrammed into neuron like cells in living animals upon depletion of USP48, ubiquitin deubiquitinating enzyme 48.
Who is Oktay Ismail Kaplan?
Oktay Ismail Kaplan has recently started to work as a Lecturer/Assistant Professor at the Department of Medicine in Medeniyet University, Istanbul, Turkey. Kaplan traveled to Dublin to perform his PhD at University College Dublin, Dublin, Ireland under the supervision of Dr. Oliver Blacque and received his Ph.D in Genetics from University College Dublin, Dublin, Ireland in 2011. In 2012, he joined the Tursun Lab, Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center (MDC), Berlin, Germany to carry out his postdoctoral studies and was subsequently awarded both an EMBO Long-Term Fellowship and Helmholtz Postdoctoral Fellowship in 2012. His recent scientific activity focuses on the study of molecular mechanisms regulating directcell reprogramming.